



Vaccines Safety during Emerging Infections and Issues of Special Populations and Minority Groups

Guest Editors:

**Dr. Ahmed Ibrahim
Fathelrahman**

Dr. Elmoubashar Farag

Dr. Mansour Adam Mahmoud

Dr. Asim Ahmed Elnour

Deadline for manuscript
submissions:
closed (31 October 2023)

Message from the Guest Editors

Objectives:

- How to communicate vaccine-related safety issues;
- Policy making and regulations related to vaccine safety;
- How to report vaccine-related pharmacovigilance;
- How to manage vaccine side effects and adverse reactions;
- Companies versus labs versus government communications regarding vaccine safety.

Examples of special populations:

Elderly; infants; children; patients with genetic problems; patients with autism; pregnancy; patients with cancer; patients with disabilities; patients with organ damage; patients with comorbidities.

Targeted emerging infections:

- SARS;
- COVID-19;
- Nipah virus;
- Dengue virus;
- Ebola virus;
- Zika virus;
- Hepatitis;
- Monkeypox virus.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)